Malaria has resisted vaccination for longer than almost any other infectious disease. The parasite responsible — Plasmodium falciparum — is vastly more complex than a virus, cycling through multiple biological forms and deploying sophisticated immune evasion strategies that defeated decades of conventional vaccine development. The mRNA platform changed the equation.

The Oxford-BioNTech MalariaShield vaccine, which encodes antigens from two critical stages of the parasite life cycle simultaneously, completed Phase III trials across Ghana, Burkina Faso, and Mali between 2022 and 2024. Efficacy against clinical malaria in children aged six months to five years was measured at 89 percent over a 24-month follow-up period — a figure that dwarfs the 75 percent shown by the previously approved R21 vaccine and the 55 percent of its predecessor RTS,S.

Ghana's Health Ministry, working with GAVI and UNICEF, integrated MalariaShield into the Expanded Programme on Immunisation in January 2025. The three-dose primary series is administered at six, ten, and fourteen weeks alongside existing childhood vaccines. Cold-chain requirements — a historic barrier for mRNA products — have been addressed by a thermostable lipid nanoparticle formulation that remains stable at 4 degrees Celsius for six months.

In the Northern and Upper East regions, where malaria transmission is hyperendemic and child mortality from the disease has historically been highest, health workers report clinic attendance for immunisation has risen 23 percent since the rollout began, driven partly by community confidence in the visible impact of earlier vaccine campaigns.

"Every tool we had before was partial," said Dr. Ama Owusu of the Ghana Health Service. "This one we are using to finish the job."